466 results about "Group A - blood" patented technology

The invention relates to the field of medical apparatus and instruments, and in particular, relates to a multi-channel fully automatic blood type analyzer cooperatively used with a microcolumn gel card. The multi-channel fully automatic blood type analyzer includes an analyzer base; a working platform is fixed on the base; the working platform is provided with a sample adding, picking and placing mechanism and a reagent storage mechanism; the sample adding, picking and placing mechanism includes a sample adding mechanical arm and a grasping mechanical arm; the middle part of the working platform is provided with a plurality of groups of loading tracks, the loading tracks are loaded with a sample loading frame, a self-use evenly-mixing reagent loading frame, a gun head loading frame and a microcolumn gel card loading frame in turn side by side. The multi-channel fully automatic blood type analyzer is small in size and compact in design, and flexibly meets the multiple experimental functions of the system. The mechanical arms have high transmission accuracy and long service life.

An automatic blood analysis and identification system permits patient identification and other vital information, such as blood type and Rh factor, to be automatically printed directly on a container holding a bodily fluid sample almost immediately after the sample has been drawn and analyzed. There is no manual handling of the sample between the draw and the identification. The system includes a carrier unit for holding at least one clear sample container, and a printer disposed within the unit for printing information onto the sample container. A photo-analyzer analyzes a bodily fluid sample within the sample container, and sends information to the printer which prints the information onto the sample container. The system may also be configured to utilize radio frequency identification (RFID) technology to imprint electronic data bearing the information onto a microchip implanted within the sample container.

The invention provides a novel full-automatic blood type analyzer, which comprises a sample disk subsystem, a reagent sampling subsystem, a reagent distribution subsystem, a reaction disk subsystem, a blowing mixing subsystem, a digital image recording and analyzing subsystem, a reaction cup cleaning subsystem, a computer control subsystem and a software management system, wherein the subsystems are arranged on an analyzer main frame and can perform automatic sample acquisition, and blood type analysis, recording and management respectively; the sample disk subsystem, the reagent sampling subsystem, the reagent distribution subsystem, the reaction disk subsystem, the blowing mixing subsystem, the digital image recording and analyzing subsystem and the reaction cup cleaning subsystem are connected with the computer control subsystem respectively; and a software management system and a digital image recording and analyzing program are stored in a master control computer of the computer control subsystem. The novel full-automatic blood type analyzer has the characteristics of high degree of automation, high detection speed, stable performance, high analysis accuracy, low cost and application to medical establishment.

A plasma expander and blood substitute comprising a therapeutic amount if a solution of alpha-keratose, a soluble fraction of keratin, as an oncotic agent with nutrient growth properties suitable as a transport vehicle for the natural or synthetically formed elements of blood. The solution of alpha-keratose is non-antigenic, does not require blood typing, is free of disease producing viruses and may be stored indefinitely at ambient temperatures in the lyophilized state.

The present invention relates to biomedicine technology, and is especially technological process of inducing and differentiating hemopoietic stem / ancestral cell of different sources into mature red blood cell by means of the support of stroma cell in a serum-free culture system. By means of the common culturing of stroma cell originated from embryo liver or mesenchyme stem cell originated from embryo marrow and erythron ancestral cell in different extracorporeal induction stages, the present invention realizes complete denucleation of erythrocyte to create erythrocyte with complete function. The present invention makes it possible to provide great amount of general or rare hematypic erythrocyte products for medical application.

Living cells are modified at their surface with specially selected polymers. Covalently attaching specially selected polyethylene glycol (PEG) derivatives to the surface of red blood cells (RBC) in aqueous media under mild conditions is a preferred example. The selected PEG derivatives dramatically reduced aggregation and low shear viscosity of RBC resuspended in autologous plasma, and inhibited RBC agglutination by blood group-specific antibodies. The morphology and deformability of the PEG-treated cells were unaltered. PEG coating of the RBC surface is applicable to the treatment of a variety of diseases characterized by vaso-occlusion or impaired blood flow, e.g., myocardial infarction, shock, and sickle cell disease. An infusion solution is prepared containing red blood cells covalently bound to a PEG derivative having a molecular weight of between 2,000 and 5,000 Daltons and a PEG derivative having a molecular weight between 10,000 and 35,000 Daltons.

RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC / c, RhE / e, S / s, K / k, Kpa / b, Fya / b, FYO, Jka / b, Dia / b, and HPA-1a / b.

Novel hybrid fusion peptides are disclosed. The novel peptides are formed by the fusion of two or more components. One component is a peptide sequence or variant of a peptide sequence derived from a malaria parasite merozoite peptide which has affinity for and binding capability to red blood cells.In particular segments of the glycophorin binding peptide 130 (GBP130), are preferred for the first component. Also disclosed are alternative first components, the glycophorin binding peptide homologues (GBPH), or the erythrocyte binding antigen 175 (EBA175), or the plasmodium vivax Duffy receptor or the pre major merozoite surface antigen PMMSA or the (P200) peptide.The first component peptide is fused to all or part of a peptide segment derived from the CD4 molecule or part thereof or variant thereof which shows binding affinity for the HIV virus.The resulting fusion peptide being exemplified asNH2-CD4-GBP130-COOH1-371 201-774Also disclosed are the methods of manufacture and means to use the novel hybrid peptides as clinical agents to treat, prevent or test for HIV infection.

The invention provides a polymerase chain reaction-sequence based typing (PCR-SBT) method for ABO blood type genotyping. The method comprises the following steps of: preparing human genome DNA; amplifying segments of ABO gene exon 1, exons 2-4 and exons 5-7; performing double enzyme digestion purification on the obtained amplified products; performing a sequencing PCR reaction on the purified products; purifying the sequenced products by a sodium acetate-ethanol precipitation method and performing capillary electrophoresis sequencing; and analyzing the obtained sequences by using software to determine the genotype. The method has the advantages of solving the problems of identification of an ABO subtype, judgment of difficult blood types, discovery of a new mutational site, gene recombination among genes, genetic polymorphism detection and the like, exerting the characteristics of high flux and result accuracy of ABO genotyping operation by PCR-SBT, achieving great importance for the relative application in the fields of clinical transfusion medicinal research, genetics and the like and having important practical significance for medicinal research units, pharmic research and reagent development units.

The invention relates to a method for fast testing human ABO / Rh / MN blood type and a kit used in the method. The method and the testing kit follow the principle of immunochromatography and realize the blood type test by observing whether residual red substances resulted from the agglutination of erythrocytes exist or not after the antigen antibody reaction of blood type substances. The method has simple operation and can avoid various defects in present ordinary blood type testing methods. In the method, the loading amount of tested blood sample is no more than 10 microliter, and the whole test process lasts no more than 2 minutes.

The present invention relates to an improved method for enzymatically removing blood type-specific antigens from erythrocytes, comprising titrating the pH of the erythrocytes first to a pH suitable for enzyme activity and then, once the desired extent of antigen removal has been achieved, to a pH appropriate for storage and / or transfusion. The buffers used for titration have pH values significantly above or below the target pHs for erythrocyte conversion or storage / transfusion. The invention is based, at least in part, on the discovery that the structural integrity of the erythrocytes is not substantially disrupted by titration. The present invention further relates to methods wherein the addition of polyethylene glycol improves the efficiency of enzymatic removal of erythrocyte antigens.

A red cell membrane antigen magnetic bead kit and an application in blood type antibody test belong to the biological technical field, for using red cell membrane antigen magnetic beads to prepare a kit and provide the application in blood type antibody test. The kit comprises red cell membrane antigen magnetic beads, a U-shaped reaction plate of 96 holes and a red cell membrane antigen magnetic bead diluent. The invention has the advantages that the red cell membrane antigen magnetic beads have long storage period, thus is beneficial for the storage of red cell rare antigens.

The invention discloses a blood type result recognition algorithm based on grey level analysis and type recognition. The blood type result recognition algorithm comprises the following steps: grey level transformation, smooth filtering, slope correction, microcolumn small tube division, threshold processing, grey level analysis, type recognition and detection result comparison. The blood type result recognition algorithm adopts a method combining the grey level analysis and the type recognition to automatically recognize a blood type detection result so that the efficiency of recognizing the blood type detection result is improved; the blood type result recognition algorithm has the advantages of rapidness and accuracy; meanwhile, the effectiveness of the result recognition is improved by operations including shake elimination, the slope correction, the microcolumn small tube division, the type recognition and the like.

The invention relates to a preparation method of an ABO / RhD blood typing detection reagent card. Six microcolumn gel tubes are arranged on the reagent card and includes a gel tube containing monoclonal anti-A antibodies with IgM property, a gel tube containing monoclonal anti-B antibodies with IgM property, a gel tube containing monoclonal anti-D antibodies with IgM property, two gel tubes which are used for reverse typing and contain a gel suspending medium and a gel tube which is used as a negative control and contains the gel suspending medium. The preparation method comprises the processes of preparing the gel suspending medium, preparing gel, selecting antibodies as well as suspending and packing the gel. The ABO / RhD blood typing detection reagent card prepared by the method has highsensitivity, good specificity and stable quality and can be used for positive typing and reverse typing.

The present invention is directed to a microfluidic biochip based on an agglutination reaction that is frequently used in qualitative typing in the diagnostic medicine field by realizing a specimen inlet, a reagent inlet, a split microchannel, transfer microchannels, a chaos micromixer, a reaction microchamber, a microfilter, a passive microvalve, and an outlet on a plastic microchip. Particularly, the biochip of the present invention is characterized in that portability thereof is superior and a small amount (about 1 μl) of each of a specimen and a reagent is used. In addition, the biochip of the present invention can be cheaply made through conventional photolithography, electroplating, injection molding, and bonding. Therefore, by utilizing the microfluidic biochip for blood typing according to the present invention, a point-of-care diagnosis for performing blood typing based on an agglutination reaction at any place becomes possible.

The invention discloses a reverse typing colloidal gold kit for ABO blood groups and a preparation method thereof. The reverse typing colloidal gold kit for the ABO blood groups comprises a reacting plate, erythrocyte membrane antigen gold particles and a basic solution, wherein 3N reaction holes are formed in the reacting plate and are respectively used for placing A erythrocyte membrane antigen gold particles and a basic solution, B erythrocyte membrane antigen gold particles and a basic solution, and O erythrocyte membrane antigen gold particles and a basic solution; the reaction holes are of circular structures, the bottoms of the holes are smooth and U-shaped; and sealing covers are arranged on the reaction holes. The kit also can be a dry kit; and the erythrocyte membrane antigen gold particles and the basic solution are dried on the reaction holes. According to the reverse typing colloidal gold kit for the ABO blood groups and the preparation method, erythrocyte membrane blood group antigen extracts are prepared and then marked with the colloid gold, and thereby the problem that the fresh erythrocyte just can be stored in a short period can be solved. The kit has the shelf life not less than 12 months at 2 to 20 DEG C, and has the advantages of being high in sensitivity, convenient to use, and relatively low in cost, and identifying the results easily.

A method of formulating a personal care and / or fragrance product comprises selecting a specific ABO blood type and using a group of product ingredients correlated as beneficial to the selected ABO blood type to formulate the personal care product. A personal care product for use by a human of a specific ABO blood type to prevent an antibody response comprises a plurality of ingredients selected to omit one or more of the A antigen and similar compounds and the B antigen and similar compounds.

The invention belongs to the field of biological medicines and discloses an immunochromatography test paper technology, which is used for specifically measuring the negative, positive and titer of IgM, IgG and IgA blood group antibodies in blood or body fluid or tissue fluid or secretion of people. The technology comprises the following steps: (1) preparing a sample filter membrane and a sample pad; (2) preparing a tracer and a tracing pad; (3) preparing a fiber membrane detection area and a quality control area; (4) labeling a test strip; (5) assembling the test strip; (6) injecting a sample and detecting; and (7) reading a result. The test strip can be used for measuring IgM anti-A and anti-B antibody titer, monitoring implantation of bone marrow transplantation and measuring the titer of immune IgG anti-A and anti-B antibodies of individuals, particularly prenatal pregnant women and newborns, the reverse typing of blood groups can be accurately judged by specifically measuring the IgM anti-A and anti-B antibodies, and the reverse typing of the blood group of an individual can be judged through saliva without blood sampling by specifically measuring IgA anti-A and anti-B antibodies in secretion.

The invention relates to a method for the immunodetection of human blood group antibodies, particularly relating to a method and a used detection strip for rapidly detecting human blood group antibodies. The method comprises the following steps: a blood group antigen is precoated on a solid-phase carrier; the blood group antigen with a signal mark is fixed on a fiber mat adhered on one end of the carrier; and a sample is added dropwise, if the sample to be detected contains an antibody which can be combined with the blood group antigen, a macroscopic immune complex can be observed on the solid-phase carrier, and otherwise, the macroscopic immune complex is not formed, thus the blood group antibody in the sample is detected.

The fully automatic ABO blood type identifying process in fully automatic enzyme-linked immunological analyzer includes the steps of applying sample, hatching, normal agglomeration, vibrating suspension, letting stand, reading plate, calculating and printing to output identification result. The equipment includes increased automatic centrifugal machine connected to computer in the position for the manipulator to touch and increased automatic centrifugal machine driving program in the computer. The method of the present invention has simple operation, high detection efficiency and high accuracy, and the equipment has simple structure, low cost and easy use.

The invention discloses an epitope polypeptide of blood type A antigen and sieving method with amino acid sequence at Glu-Tyr-Trp-Tyr-Cys-Gly-Met-Asn-Arg-Thr-Gly-Cys or Gln-Ile-Trp-Tyr-Glu-Arg-Thr-Leu-Pro-Phe-Thr-Phe, which comprises the following steps: using NaHCO3 buffer to dilute blood type A antigen specific monoclonal antibody and cover ELISA board; adding bacteriophage into pore with monoclonal antibody; using glycine-alcaine buffer to elute the connected bacteriophage under indoor temperature; augumenting the bacteriophage in the host bacteria ER2738 after neutralizing as input in the next step; sieving for three times; cloning the 32nd bacteriophage after the third sieving; identifying to obtain the product; fitting for detecting blood type A antibody and affinity filtering.

The invention discloses a forward and reverse ABO typing and RhD blood type detecting card comprising a detecting card with six micro-columns, wherein the first three micro-columns in the six micro-columns are respectively filled with equivalent A-resistant gel, B-resistant gel and D-resistant gel, and the left three micro-columns are filled with equivalent blank gel. The forward and reverse ABO typing and RhD blood type detecting card is prepared by using the following method comprising the steps of swelling dextran gels; preparing all antibody diluents; preparing all antibody working solutions; washing the gels; and subpackaging to form the RhD blood type detecting card. According to the forward and reverse ABO typing and RhD blood type detecting card, crosslinked dextran gels with different sizes and sieving ranges are mixed and swelled by using purified water, so that the specificity is effectively ensured, meanwhile, the forward and reverse ABO typing and RhD blood type detecting card has very high sensitivity, and the ion strength of a system is effectively ensured.

This invention relates to enzymatic removal of type A and B antigens from blood group A, B, and AB reactive cells in blood products, and thereby converting these to non-A and non-B reactive cells. The invention further relates to using unique alpha N-acetylgalactosaminidases and alpha-galactosidases with superior kinetic properties for removing the immunodominant monosaccharides of the blood group A and B antigens and improved performance in enzymatic conversion of red blood cells. The preferred unique alpha-N-acetylgalactosaminidases and alpha-galactosidases exhibit the following characteristics: (i) exclusive, preferred or no less than 10% substrate specificity for the type A and B branched polysaccharide structures relative to measurable activity with simple mono- and disaccharide structures and aglycon derivatives hereof; (ii) optimal performance at neutral pH with blood group oligosaccharides and in enzymatic conversion of cells; and (iii) a favorable kinetic constant Km with mono- and oligosaccharide substrates. The conversion methods of the invention use significantly lower amounts of recombinant glycosidase enzymes than previous and result in complete sero-conversion of all blood group A and B red cells.

The invention discloses a fully-automatic blood type analysis system, which comprises a host computer, a medium machine, a card box for storing a micro-column gel card, a mechanical arm subsystem, a micro-column gel card recognition subsystem, a puncturing subsystem, a sample injection subsystem, a centrifugation subsystem and an image acquisition and processing subsystem, wherein the host computer comprises a data storage subsystem, a display subsystem and an image analysis and judgment subsystem, and transmits a command to the medium computer, the command is analyzed by the medium computer, the analyzed command is assigned to the corresponding subsystem so as to perform the command task, and the performing result is fed back to the host computer through the medium machine. According to the present invention, with the analysis system, the micro-column gel card having the remaining holes can be reused, such that the waste of the remaining holes can be avoided, the use efficiency of the micro-column gel card is effectively improved, and the experimental cost is reduced; and the micro-column gel card is subjected to automatic classification collection according to the recognition result during the experiment process, such that the misoperation easily occurring during the manual classification is avoided, the repeated recognition work is avoided, and the efficiency of the analysis experiment is improved.

Red blood cell membrane derived microparticles (RMP) are safe, economical, effective hemostatic agents in the treatment of a wide range of bleeding conditions and can be considered as universal hemostatic agents. RMP are produced from red blood cells using a high-pressure extrusion membrane shear process and can be lyophilized after production and retain activity even when stored at room temperature. RMP can be administered to original donors (autologous treatment), thus avoiding transfusion complications, or can be administered to blood type compatible recipients. RMP produced from type O, Rh negative red cells can be given to any person regardless of blood type. RMP can be administered to reduce excessive bleeding resulting from trauma, surgeries, invasive procedures and various bleeding disorders such as platelet disorders, either congenital or acquired, and coagulation disorders, either congenital or acquired.

The invention discloses a blood bank information management method and a blood bank information management system, wherein the blood bank information management method comprises: receiving a blood bank information inquiry request message which is provided with blood type information; inquiring corresponding blood bank capacity information according to the blood type information in a blood bank information database, and returning the blood bank capacity information. A blood bank information updating method comprises: receiving a blood bank information updating request message which is provided with the blood type information and capacity information; updating the blood bank capacity information in the blood bank information database according to the blood type information and the capacity information. The invention also provides a blood bank information automatic scrapping method. The blood bank information management system comprises a public client, a blood collecting point client, a blood bank client, a hospital client and a collaboration medical information platform. The invention realizes the effective management for the information in the blood bank, saves society human cost, and improves the disease treatment efficiency of the hospital.

The invention discloses portable type blood type system detection test paper. The test paper is composed as follows: a solid-phase carrier is provided with a detection channel; a sample feeding cushion, an antibody cushion or an antigen cushion, a swimming cushion, a reaction cushion and a water absorption cushion are overlapped on the detection channel in sequence; the antibody cushion pre-coats a blood type detection agent; and a developing reagent is fixedly arranged on the reaction cushion. The test paper can be used for rapidly and accurately detecting a plurality of blood type systems including ABO, Rh, MNS, Kell, Kidd and the like, can be used for selecting items according to POCT detection requirements and can be suitable for various conditions including hospitals, families, wild emergency and the like.

A method of examining blood type and an apparatus for examining blood type using the method are presented. According to the method, the blood type is examined once the blood is injected into the apparatus, and the result of examination is kept safely. The method comprises introducing the reagents into the plural reagent chambers respectively; flowing the blood into each of reagent chambers and mixing them with the reagents; filtering the mixture of blood; and flowing the mixture of blood which passed the filters-into the reading channels. The introduced blood is passed the micro channels and reacted with the reagents, and the results are obtained from filtering the mixture of blood. Thus, even small quantity of blood may be examined easily and clearly. Further, the results of examination are easily read and kept. The apparatus may be carried out and used with convenience.

The invention relates to a testing method for red corpuscle blood group antigen. It takes the processes of over pre-dilution, reacting, and testing, respectively testing the reacting system formed by tested red corpuscle and blood group antibody that is already known and the red corpuscle parameter of the comparing system constructed by the tested red corpuscle suspension without blood group antibody, gaining the alteration of the two system red corpuscle parameters, taking comparison analysis to the restricted range to judge whether the agglutination reaction is occurred and indirectly testing whether the tested red corpuscle has the blood type antibody corresponding to that has already been known.